BMY.US Weekly Report · 2026-W30
BMY closed at $62.09 this week, up 2.2% from the Monday opening of $60.16. The momentum is driven by two catalysts: Bristol Myers’ partnership with NVIDIA to build an AI drug discovery platform, and FDA acceptance of mezigdomide’s NDA for multiple myeloma treatment. Valuations stand at historic lows, yet institutional ownership distribution and capital flows remain cautious, creating a disconnect between fundamentals and market sentiment.
Price Action
The stock advanced 1.35 points across five trading sessions this week. After Monday’s close at 60.16, the price climbed to 60.93 on Tuesday, pulled back slightly to 60.76 on Wednesday, rebounded to 61.51 on Thursday, and finished at 62.09 on Friday, marking a new swing high for the recent rally.
Weekly range totaled 3.02 points (high 62.82 vs. low 59.80), representing a 4.97% oscillation from the prior week’s close of 60.74—a moderate volatility level. Friday’s trading volume hit 12.07 million shares, significantly above the daily average of roughly 7.5 million from Monday through Thursday, suggesting incremental buyer participation at higher levels.
Weekly turnover rate stands at 0.59%, consistent with the 60-day median, indicating steady but unremarkable trading interest. The candlestick pattern shows a break above early-week consolidation on Friday’s volume, approaching recent resistance, though conviction for a sustained breakthrough remains uncertain.
Valuation and Earnings
Current P/E of 17.43x places the stock at the 3.56th percentile of its five-year trading history—meaning valuations have been lower less than 4% of the time over the past five years. This represents an exceptionally attractive entry point relative to historical norms.
Most recent quarter (Q1 2026) delivered EPS of $1.31, a 9.17% year-over-year gain; operating revenue of $11.49 billion, up 2.57% YoY; and net profit of $2.677 billion, up 9% YoY. Profitability remains steady with a net margin of 23.3%, reflecting solid earnings quality.
Against consensus EPS expectations of $6.124 for full-year 2026, with Q1 already delivering $1.31, the remaining three quarters must contribute approximately $4.81 per share—consistent with prior full-year run rates and suggesting reasonable predictability.
Capital Flows and Institutional Views
Capital flows this week present a mixed picture. Large-cap institutions saw net outflows of $1,168.79 million; retail investors posted net outflows of $56.03 million; only mid-cap institutions captured net inflows of $584.36 million. Both institutional and retail money departed simultaneously, with mid-cap players offering partial support—a striking contrast given the rock-bottom valuations and positive news backdrop.
Analyst coverage spans 29 votes: 6 buys, 4 outperforms, 17 holds, 1 sell, and 1 no opinion. While holds dominate at 58.6%, combined buy/outperform support of 34.5% is not inconsequential. The consensus price target of $62.96 sits barely above Friday’s close of $62.09, implying limited upside in the near term and suggesting cautious-to-neutral positioning on current valuations.
Note that analyst ratings typically lag price action. These assessments were updated July 20 when the stock traded at 60.16; the subsequent 3.2% rally may already have outpaced the ratings’ implied expectations.
Weekly News
Two themes dominated coverage this week: innovation and pipeline progress.
Bristol Myers’ collaboration with NVIDIA to construct a “most powerful” AI factory for life sciences addresses the broader AI compute infrastructure boom while strengthening BMY’s drug discovery competitive moat. FDA acceptance of mezigdomide’s NDA for multiple myeloma, with a May 13, 2027 decision target, establishes a concrete new product milestone and growth visibility.
Other coverage:
- Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co.
- Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory
- Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI
- Bristol Myers buys Nvidia’s latest AI computing system for drug research
- FDA accepts Bristol Myers NDA for mezigdomide in multiple myeloma, sets May 13, 2027 decision date
- Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo
- Bristol-Myers Squibb (BMY) Receives a Hold from Citi
- Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled
- Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled
- Bristol-Myers Squibb’s Q2 2026 Earnings: What to Expect
Summary
BMY’s weekly advance continues a multi-week recovery, anchored by genuinely attractive valuations, steady earnings growth, and substantive product catalysts in AI-partnered drug discovery and NDA advancement. Yet institutional ownership remains cautiously positioned and both institutional and retail money flowed outward this week—a curious contrast. The disconnect between valuation fundamentals and actual capital behavior suggests market consensus on this price level remains unformed. Meaningful conviction may require either broader sentiment shift or incremental event catalysts. Q2 earnings and ongoing regulatory progress on pipeline assets warrant close monitoring in coming weeks.